glp-1 receptor agonist agent agonists show promise in treating substance use disorders Chemical structures of GLP-1 receptor

You're likely a reasonable candidate if: You've been symptomatic for more than 12 weeks with confirmed or highly probable prior SARS-CoV-2 infection Standard care has not produced adequate improvement You have a clear symptom cluster that maps to one or more of the mechanisms above You're willing to undergo baseline labs and ongoing clinical monitoring You understand that peptide therapy is an emerging not established intervention for this indication You may need to address other issues first if: Active autoimmune conditions are not yet stabilised You have unmanaged cardiovascular disease You're currently immunosuppressed for another reason You haven't yet tried evidence-based long COVID rehabilitation approaches The most important step is working with a clinician who understands both long COVID pathophysiology and peptide pharmacology not one who simply offers a generic protocol

At the same time, MKLP2 activates ARK5 or ARK5 inhibits PP1 activity, thereby decreasing GSK3 activity, increasing nuclear translocation of Nrf2 and inhibiting ferroptosis [120]

Shang, J

& Xu, Q.-H